Bristol Myers data make case for earlier use of bone marrow disease drug

Bristol Myers data make case for earlier use of bone marrow disease drug

Submitted by admin on May 25, 2023 - 8:31pm
Source: 
BioPharma Dive
News Tags: 
Bristol Myers Squibb
Reblozyl
Epogen
myelodysplastic syndromes
clinical trials
Headline: 
Bristol Myers data make case for earlier use of bone marrow disease drug
snippet: 

Trial results published Thursday show Bristol Myers’ Reblozyl outperformed the decades-old standard Epogen in treating anemia from myelodysplastic syndromes.

Do Not Allow Advertisers to Use My Personal information